NVDAMillionaire Posted - 1 day ago

$MASI Masimo Corporation (MASI): A Diversified Medtech Leader Navigating Challenges and Opportunities https://beyondspx.com/article/masimo-corporation-masi-a-diversified-medtech-leader-navigating-challenges-and-opportunities

No_Stress_Invest Posted - 1 week ago

$MASI $OWLT $TSLA I am all for it but $5 billion sounds crazy. This thing would have to become a meme stock to get to $5 billion market cap

Ankerbanker Posted - 1 week ago

$OWLT $MASI $TSLA What if Owlet’s baby health data could power Tesla’s robot (Optimus), transforming it into a proactive caregiver? Imagine the Tesla Bot monitoring infant health, alerting parents to issues like low oxygen levels, or even soothing a baby while parents are occupied. This integration could revolutionize in-home care, making Tesla’s robot an indispensable tool for families. As Tesla refines its AI, Owlet’s data could enhance the bot’s responsiveness, elevating its value. Could this collaboration open up entirely new markets for Owlet, positioning it as a leader in family-focused tech? If so, Owlet’s valuation could skyrocket, potentially surpassing $5 billion as it taps into Tesla’s vast ecosystem and redefines caregiving with AI.

trendx Posted - 2 weeks ago

Buying $MASI if crosses and sustains above $ 176 SL - 173 TARGET - 208.7

swingtradesmastermind Posted - 2 weeks ago

Hello all, Our picks' returns this week of 12/03/24 are as follows: $TSLA: +10.82% $MASI: -1.10% $FIX: +1.63 $ZM: +4.87 $ZIM: + 10.52 An average of 5% vs 0.8% for S&P500 I hope you all made some money!

Estimize Posted - 2 weeks ago

Wall St is expecting 1.42 EPS for $MASI Q4 [Reporting 03/04 AMC] http://www.estimize.com/intro/masi?chart=historical&metric_name=eps&utm_co

swingtradesmastermind Posted - 3 weeks ago

Hello all, Our swing picks for this week are: $TSLA, $MASI, $FIX, $ZM, $ZIM Have a great week!

TalkMarkets Posted - 11/30/24

Buy 5 Mid-Cap Stocks Poised To Turn Into Large-Caps In 2025 $CRS $MASI $MTSI $INGR $DRS https://talkmarkets.com/content/stocks--equities/buy-5-mid-cap-stocks-poised-to-turn-into-large-caps-in-2025?post=471324

TickerDD_com Posted - 11/29/24

Play Stonk Trivia! 5 Strangest Market Events for $MASI and its company Masimo https://youtu.be/UyEnJ1VUYaM

TickerDD_com Posted - 11/29/24

Play Stonk Trivia! 5 Competitors for $MASI and its company Masimo https://youtu.be/B6sRQI1lYQQ

Thestocktraderhubzee Posted - 1 month ago

$MASI Stifel Reiterates Buy on Masimo, Raises Price Target to $190

FlynancialAnalyst Posted - 1 month ago

$MASI $8.70B mc $XLV name still needs a lot of work imo, but keep an eye on it. Significant accumulation this year, now trading at 1yr highs LONG-time (1990s) founder led, 8.15% insider owned. I'll be watching for a nearly certain sharp rise in Pct of all funds long shares following this week's fresh data Short float % trending lower YTD TrendEdge.app/asset/MASI

Luii_133 Posted - 1 month ago

$MASI 37% since this

1986iamwallstreet Posted - 1 month ago

$MASI dying business here

DonCorleone77 Posted - 1 month ago

$MASI Masimo raises FY24 EPS view to $3.95-$4.10 from $3.80-$4.00 Consensus $3.88. Cuts FY24 revenue view to $2.075B-$2.105B form $2.085B-$2.135B, consensus $2.1B.

DonCorleone77 Posted - 1 month ago

$MASI Masimo sees Q4 adjusted EPS $1.35-$1.50, consensus $1.41 Sees Q4 revenue $581M-$611M, consensus $607.35M.

DonCorleone77 Posted - 1 month ago

$MASI Masimo reports Q3 adjusted EPS 98c, consensus 84c Reports Q3 revenue $504.6M, consensus $502.67M. Michelle Brennan, Interim Chief Executive Officer of Masimo, said, "We are pleased to report strong third quarter performance, driven by our core healthcare segment. We appreciate the commitment and energy of our employees, which has resulted in a seamless transition since our Annual Meeting with no disruption to our business or departures of critical talent. Our focus is on positioning Masimo to achieve its significant long-term growth potential by capitalizing on the many opportunities we see ahead of us, including through our ongoing review of the product portfolio and R&D projects. We are allocating resources to fewer projects, concentrating on sizable market opportunities that address clear unmet needs, and reducing spending in areas that are not contributing to our long-term growth objectives. We are also progressing on our strategic review of the consumer business and are focused on delivering the best outcome for our shareholders. We are confident in our position as we approach the end of 2024, as demonstrated by our increased full-year non-GAAP operating margin and EPS guidance. With the support of our talented team and our newly expanded Board, we will continue to execute on our strategy while enhancing shareholder value as we look to next year and beyond."

1986iamwallstreet Posted - 1 month ago

$MASI lower revenue. Flush city …..

ChessGM Posted - 1 month ago

$MASI Heads up alert! Only three days until Upcoming Earnings on Tuesday, 11/5/2024 Bearish (2.5) In the case of Masimo Corporation (NASDAQ: MASI), recent developments suggest a challenging landscape for the company. The termination of CEO Joe Kiani, following a contentious proxy battle with activist investors, raises concerns about the company's leadership stability. While Masimo has reported positive expectations regarding earnings growth and has received a price target increase from BTIG, the overall sentiment appears dampened by the leadership change and its potential impact on operational continuity. Financial metrics indicate that Masimo's P/E ratio stands at approximately 30, reflecting a premium valuation relative to the industry average of around 25. This premium is supported by a projected EPS growth rate of 12% for the upcoming year, suggesting optimism in its earnings potential. However, revenue forecasts have become less certain, especially after a jury ruled in favor of Apple in a patent infringement case against Masimo, which may affect future sales of its smartwatch products. Comparatively, the broader MedTech sector is experiencing robust growth, but Masimo faces headwinds that could hinder its competitiveness. Upcoming earnings reports are expected to reveal third-quarter financial results on November 5, 2024. Analysts are largely optimistic, with consensus estimates predicting a slight increase in revenue, driven by strong demand for Masimo's innovative medical devices. Historically, the company has shown a solid track record of beating earnings estimates, which may provide some reassurance to investors amid current uncertainties. The market will keenly watch the conference call for insights into how the leadership transition is being managed and its implications for future growth. Given the mixed signals surrounding Masimo's outlook, the potential impact of the earnings report will be crucial in determining the stock's direction in the near term. - Funds were net buyers of $MASI during the previous reporting quarter. - Top 5 funds with large holdings in $MASI: * RTW Investments LP $184MM. CGMRank: 61% * Westfield Capital Management Company LP $143MM. CGMRank: 82% * Farallon Capital Management LLC $141MM. CGMRank: 69% * Holocene Advisors LP $131MM. CGMRank: 85% * Point72 Asset Management LP $85MM. CGMRank: 86% - Last 10 days performance: 0% - Last 30 days performance: 6% - Last 90 days performance: 35% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.

contangoz Posted - 10/29/24

CEO BOOTED $MASI

swingingtech Posted - 10/28/24

$NPCE $MASI https://wallstreetwaves.com/strength-seen-in-neuropace-npce-can-its-5-1-jump-turn-into-more-strength/

swingingtech Posted - 2 months ago

$MASI https://wallstreetwaves.com/exploring-intriguing-masi-options-strategies-for-june-2025-puts-and-calls/

WeeklyTrader Posted - 2 months ago

Brace yourself, $MASI is dropping! RSI: 70.47% 50-day MA: $123.65 200-day MA: $126.11

WeeklyTrader Posted - 2 months ago

What’s your vibe on $MASI today? RSI: 67.02% 50-day MA: $122.89 200-day MA: $125.96

WeeklyTrader Posted - 2 months ago

t’s spill the tea on $MASI's rise!

DonCorleone77 Posted - 09/30/24

$AAPL $MASI Apple rethinking approach to headsets, Bloomberg reports Apple (AAPL) is considering options for its headsets, including keeping the Vision Pro more or less the same but focusing on a less expensive version, Bloomberg's Mark Gurman reports. The company could also follow up with a second-generation version of the original, higher-end Vision Pro that has a new chip and Apple Intelligence. Apple could remove the on-board computer and external battery from the Vision Pro and shift many of the internal functions over to the iPhone. Apple is working on a new version of the AirPods Pro that uses external cameras and artificial intelligence to understand the outside world and provide information to the user, Gurman says. Apple could ultimately release some or all of these products, but Gurman says there isn't a consensus on how it will approach the headsets, but says that the resignation of Masimo (MASI) CEO Joe Kiani could open the door for lawyers from Apple and Masimo to work out a deal to bring blood-oxygen sensing back to new Apple Watches.

David4W Posted - 09/26/24

$MASI what a play by Koffey…

JackDarwin Posted - 2 months ago

$MASI Nice Gap Up Formed.

MaverikIT Posted - 3 months ago

@IsabellaDC @net0trader $MASI $DUOL

DonCorleone77 Posted - 3 months ago

$MASI Masimo provides update on consumer business review The company said, "The Board remains committed to the previously announced review of alternatives for both the consumer audio and consumer healthcare businesses. The Board has engaged Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as a legal advisor. The Board looks forward to providing updates in the near-term regarding value-creation initiatives, including this strategic review."